Adding flubendazole to standard chemo and radiation for high-grade glioma
Official title: Flubendazole Added to Standard Concurrent Chemoradiotherapy With Temozolomide in Patients With High-Grade Glioma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests adding a drug called flubendazole to the usual treatment for high-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary.
Read our full plain-language summary
What the trial team says
This study To evalute the efficacy and safety of adding flubendazole to standard concurrent chemoradiotherapy with temozolomide in patients with high grade glioma and also to evaluate DFS,OS for those patients in clinical oncology department , Assiut university Hospital .
Key facts
- Registry number
- NCT07847476
- Stage of testing
- Not applicable
- Conditions studied
- Glioma Patients
Where it is running
No locations are listed for this trial. The trial's own page may have more.
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.